vs
Side-by-side financial comparison of Moderna (MRNA) and Worthington Steel, Inc. (WS). Click either name above to swap in a different company.
Moderna is the larger business by last-quarter revenue ($1.0B vs $871.9M, roughly 1.2× Worthington Steel, Inc.). Worthington Steel, Inc. runs the higher net margin — 2.2% vs -19.7%, a 21.8% gap on every dollar of revenue. On growth, Worthington Steel, Inc. posted the faster year-over-year revenue change (18.0% vs -45.4%). Worthington Steel, Inc. produced more free cash flow last quarter ($74.6M vs $-880.0M). Over the past eight quarters, Worthington Steel, Inc.'s revenue compounded faster (3.9% CAGR vs -45.0%).
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
Worthington Enterprises, Inc. is an American industrial manufacturing company headquartered in Columbus, Ohio. The company is composed of two business segments, consumer products and building products. Within these segments, the company designs and manufactures pressure vessels such as propane, oxygen and helium tanks, refrigerant and industrial cylinders, camping and residential use cylinders, water system tanks for storage, treatment, heating, expansion and flow control, as well as a variet...
MRNA vs WS — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $871.9M |
| Net Profit | $-200.0M | $18.8M |
| Gross Margin | 79.6% | 10.7% |
| Operating Margin | -25.6% | 2.5% |
| Net Margin | -19.7% | 2.2% |
| Revenue YoY | -45.4% | 18.0% |
| Net Profit YoY | -1638.5% | 46.9% |
| EPS (diluted) | $-0.51 | $0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $871.9M | ||
| Q3 25 | $1.0B | $872.9M | ||
| Q2 25 | — | $832.9M | ||
| Q1 25 | — | $687.4M | ||
| Q4 24 | $966.0M | $739.0M | ||
| Q3 24 | $1.9B | $834.0M | ||
| Q1 24 | — | $805.8M | ||
| Q4 23 | $2.8B | $808.0M |
| Q4 25 | — | $18.8M | ||
| Q3 25 | $-200.0M | $36.8M | ||
| Q2 25 | — | $55.7M | ||
| Q1 25 | — | $13.8M | ||
| Q4 24 | $-1.1B | $12.8M | ||
| Q3 24 | $13.0M | $28.4M | ||
| Q1 24 | — | $49.0M | ||
| Q4 23 | $217.0M | $-6.0M |
| Q4 25 | — | 10.7% | ||
| Q3 25 | 79.6% | 13.2% | ||
| Q2 25 | — | 15.2% | ||
| Q1 25 | — | 11.8% | ||
| Q4 24 | 23.5% | 10.8% | ||
| Q3 24 | 72.4% | 12.0% | ||
| Q1 24 | — | 14.9% | ||
| Q4 23 | 67.0% | 7.5% |
| Q4 25 | — | 2.5% | ||
| Q3 25 | -25.6% | 5.5% | ||
| Q2 25 | — | 8.0% | ||
| Q1 25 | — | 2.7% | ||
| Q4 24 | -129.0% | 2.6% | ||
| Q3 24 | -3.8% | 5.2% | ||
| Q1 24 | — | 8.2% | ||
| Q4 23 | 0.2% | -1.1% |
| Q4 25 | — | 2.2% | ||
| Q3 25 | -19.7% | 4.2% | ||
| Q2 25 | — | 6.7% | ||
| Q1 25 | — | 2.0% | ||
| Q4 24 | -115.9% | 1.7% | ||
| Q3 24 | 0.7% | 3.4% | ||
| Q1 24 | — | 6.1% | ||
| Q4 23 | 7.7% | -0.7% |
| Q4 25 | — | $0.37 | ||
| Q3 25 | $-0.51 | $0.72 | ||
| Q2 25 | — | $1.11 | ||
| Q1 25 | — | $0.27 | ||
| Q4 24 | $-2.91 | $0.25 | ||
| Q3 24 | $0.03 | $0.56 | ||
| Q1 24 | — | $0.98 | ||
| Q4 23 | $0.63 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $89.8M |
| Total DebtLower is stronger | — | $72.1M |
| Stockholders' EquityBook value | $9.3B | $1.1B |
| Total Assets | $12.1B | $2.1B |
| Debt / EquityLower = less leverage | — | 0.06× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $89.8M | ||
| Q3 25 | $1.1B | $78.3M | ||
| Q2 25 | — | $38.0M | ||
| Q1 25 | — | $63.3M | ||
| Q4 24 | $1.9B | $52.0M | ||
| Q3 24 | $1.6B | $36.0M | ||
| Q1 24 | — | $60.8M | ||
| Q4 23 | $2.9B | $214.4M |
| Q4 25 | — | $72.1M | ||
| Q3 25 | — | $73.4M | ||
| Q2 25 | — | $151.5M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $115.0M | ||
| Q3 24 | — | $122.2M | ||
| Q1 24 | — | $147.2M | ||
| Q4 23 | — | $195.0M |
| Q4 25 | — | $1.1B | ||
| Q3 25 | $9.3B | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | $10.9B | $1.0B | ||
| Q3 24 | $11.9B | $1.0B | ||
| Q1 24 | — | $937.6M | ||
| Q4 23 | $13.9B | $1.0B |
| Q4 25 | — | $2.1B | ||
| Q3 25 | $12.1B | $2.2B | ||
| Q2 25 | — | $2.0B | ||
| Q1 25 | — | $1.8B | ||
| Q4 24 | $14.1B | $1.7B | ||
| Q3 24 | $15.8B | $1.8B | ||
| Q1 24 | — | $1.8B | ||
| Q4 23 | $18.4B | $1.9B |
| Q4 25 | — | 0.06× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.14× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.12× | ||
| Q1 24 | — | 0.16× | ||
| Q4 23 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-847.0M | $99.3M |
| Free Cash FlowOCF − Capex | $-880.0M | $74.6M |
| FCF MarginFCF / Revenue | -86.6% | 8.6% |
| Capex IntensityCapex / Revenue | 3.2% | 2.8% |
| Cash ConversionOCF / Net Profit | — | 5.28× |
| TTM Free Cash FlowTrailing 4 quarters | $-1.9B | $72.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $99.3M | ||
| Q3 25 | $-847.0M | $-6.3M | ||
| Q2 25 | — | $53.9M | ||
| Q1 25 | — | $53.8M | ||
| Q4 24 | $825.0M | $68.0M | ||
| Q3 24 | $-1.6B | $54.6M | ||
| Q1 24 | — | $44.7M | ||
| Q4 23 | $622.0M | $139.9M |
| Q4 25 | — | $74.6M | ||
| Q3 25 | $-880.0M | $-35.7M | ||
| Q2 25 | — | $8.4M | ||
| Q1 25 | — | $25.2M | ||
| Q4 24 | $303.0M | $33.2M | ||
| Q3 24 | $-1.7B | $33.1M | ||
| Q1 24 | — | $22.3M | ||
| Q4 23 | $402.0M | $121.0M |
| Q4 25 | — | 8.6% | ||
| Q3 25 | -86.6% | -4.1% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 3.7% | ||
| Q4 24 | 31.4% | 4.5% | ||
| Q3 24 | -92.2% | 4.0% | ||
| Q1 24 | — | 2.8% | ||
| Q4 23 | 14.3% | 15.0% |
| Q4 25 | — | 2.8% | ||
| Q3 25 | 3.2% | 3.4% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | 4.2% | ||
| Q4 24 | 54.0% | 4.7% | ||
| Q3 24 | 8.1% | 2.6% | ||
| Q1 24 | — | 2.8% | ||
| Q4 23 | 7.8% | 2.3% |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | -0.17× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | 3.90× | ||
| Q4 24 | — | 5.31× | ||
| Q3 24 | -120.46× | 1.92× | ||
| Q1 24 | — | 0.91× | ||
| Q4 23 | 2.87× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
WS
| Direct | $844.1M | 97% |
| Toll | $27.8M | 3% |
